Get the Stockscreener App
36.98
0.68%
0.25
After Hours:
37.01
0.03
+0.08%
Cogent Biosciences Inc stock is traded at $36.98, with a volume of 1.72M.
It is up +0.68% in the last 24 hours and up +5.03% over the past month.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.
See More
Previous Close:
$36.73
Open:
$36.92
24h Volume:
1.72M
Relative Volume:
0.88
Market Cap:
$6.32B
Revenue:
-
Net Income/Loss:
$-328.94M
P/E Ratio:
-15.10
EPS:
-2.4483
Net Cash Flow:
$-266.00M
1W Performance:
+1.76%
1M Performance:
+5.03%
6M Performance:
+156.45%
1Y Performance:
+563.91%
1-Day Range:
$35.92
$37.29
1-Week Range:
$35.17
$37.29
52-Week Range:
$4.55
$43.73
Cogent Biosciences Inc Stock (COGT) Company Profile
Name
Cogent Biosciences Inc
Sector
Industry
Phone
617-945-5576
Address
275 WYMAN STREET, WALTHAM
Compare COGT vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
COGT
Cogent Biosciences Inc
|
36.98 | 6.27B | 0 | -328.94M | -266.00M | -2.4483 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Cogent Biosciences Inc Stock (COGT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-16-26 | Resumed | Jefferies | Buy |
| Nov-10-25 | Upgrade | Stifel | Hold → Buy |
| Nov-10-25 | Upgrade | Wedbush | Neutral → Outperform |
| Oct-16-25 | Initiated | Stifel | Hold |
| Sep-03-25 | Initiated | Raymond James | Strong Buy |
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Dec-11-24 | Downgrade | Needham | Buy → Hold |
| Feb-26-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Feb-08-24 | Initiated | Citigroup | Buy |
| Dec-11-23 | Downgrade | Wedbush | Outperform → Neutral |
| Dec-08-23 | Initiated | JP Morgan | Overweight |
| Apr-28-23 | Initiated | Robert W. Baird | Outperform |
| Mar-27-23 | Resumed | H.C. Wainwright | Buy |
| Dec-14-22 | Initiated | Needham | Buy |
| Jun-28-22 | Initiated | Guggenheim | Buy |
| Oct-11-21 | Initiated | H.C. Wainwright | Buy |
| Jun-09-21 | Resumed | Jefferies | Buy |
| Dec-23-20 | Initiated | Piper Sandler | Overweight |
| Oct-14-20 | Initiated | Ladenburg Thalmann | Buy |
View All
Cogent Biosciences Inc Stock (COGT) Latest News
Cogent Biosciences Reports Recent Business Highlights and First Quarter 2026 Financial Results - Investing News Network
Cogent Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Cogent Biosciences (NASDAQ:COGT) Releases Earnings Results - MarketBeat
Bezuclastinib NDAs and cash into 2028 at Cogent Biosciences (NASDAQ: COGT) - Stock Titan
Cogent Biosciences 1Q 2026: Net loss $(97.4)M, EPS $(0.53) — 10-Q Summary - TradingView
Biotechnology company Cogent Biosciences, Inc.'s latest financial data shows that as of the end of the first quarter of 2026, the company held a total of $866.4 million in cash and cash equivalents. - Bitget
Cogent Biosciences (COGT) boosts cash to fund bezuclastinib NDAs and launch plans - Stock Titan
Cogent Biosciences Q1 net loss widens on higher expenses - TradingView
Cogent plans two bezuclastinib launches, says cash lasts into 2028 - Stock Titan
BRIEF-Cogent Biosciences Q1 Income From Operations USD -103.607 Million - TradingView
Pictet Asset Management Holding SA Boosts Holdings in Cogent Biosciences, Inc. $COGT - MarketBeat
Cogent Biosciences, Inc. (NASDAQ:COGT) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
MSN Money - MSN
Cogent Biosciences Inc (NASDAQ:COGT) Shows Bullish Technical Breakout Setup with High Scores - ChartMill
Systemic Mastocytosis (SM) Treatment Market 2026-2035: - GlobeNewswire
Systemic Mastocytosis (SM) Treatment Market 2026-2035: Industry to More Than Double in Size, Led by Sanofi, AdvaCare Pharma, and Cogent Biosciences - Yahoo Finance
Teachers Retirement System of The State of Kentucky Invests $1.33 Million in Cogent Biosciences, Inc. $COGT - MarketBeat
Cogent Biosciences, Inc. (NASDAQ:COGT) Sees Large Drop in Short Interest - MarketBeat
Cogent Biosciences (COGT) Expected to Announce Quarterly Earnings on Tuesday - MarketBeat
Cogent Biosciences prices equity offering and 1.625% convertible senior notes - MSN
COGT Rise as FDA Accepts Bezuclastinib NDA in Non-Advanced SM - MSN
A Look At Cogent Biosciences (COGT) Valuation After New KRAS And ErbB2 Data At AACR 2026 - Sahm
The Technical Signals Behind (COGT) That Institutions Follow - Stock Traders Daily
[ARS] Cogent Biosciences, Inc. SEC Filing - Stock Titan
Cogent Biosciences (NASDAQ: COGT) details 2026 proxy, pivotal bezuclastinib wins and $901M cash - Stock Titan
COGT (Cogent Biosciences Inc.) reports wider Q4 2025 loss than consensus analyst estimates, with shares dipping 0.36 percent in today's trading.Market Buzz Alerts - Xã Thanh Hà
Cogent Biosciences reports selective pan-KRAS inhibitor CGT-1263 - BioWorld News
Cogent Biosciences (NASDAQ:COGT) Shares Cross Above Fifty Day Moving AverageShould You Sell? - MarketBeat
Cogent Biosciences Announces Oral Presentation of Positive Phase 3 PEAK Trial in Gastrointestinal Stromal Tumors at the 2026 American Society of Clinical Oncology Annual Meeting - Investing News Network
Cogent’s positive tumor trial lands an oral presentation at ASCO - Stock Titan
Cogent Biosciences Announces Oral Presentation of Positive Phase 3 PEAK Trial in Gastrointestinal Stromal Tumors (GIST) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting - marketscreener.com
Cogent Biosciences Announces Oral Presentation of Positive - GlobeNewswire
Analysts Expect Breakeven For Cogent Biosciences, Inc. (NASDAQ:COGT) Before Long - 富途牛牛
HC Wainwright & Co. Reiterates Cogent Biosciences (COGT) Buy Recommendation - MSN
Cogent Biosciences (COGT): Billionaire Stan Druckenmiller admires upside potential of this stock - MSN
Cogent Bio (COGT) Stock: Invest or Wait? (+2.93%) 2026-04-18Fast Rising Stocks - Xã Thanh Hà
Cogent Biosciences Announces Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2026 - Sahm
Is AACR 2026 KRAS and ErbB2 Data Altering The Investment Case For Cogent Biosciences (COGT)? - Sahm
Cogent Biosciences (COGT) Showcases Promising Data at AACR Annua - GuruFocus
Precision Trading with Cogent Biosciences Inc. (COGT) Risk Zones - Stock Traders Daily
Revenue Check: What is the long term forecast for Cogent Biosciences Inc stockSell Signal & Reliable Entry Point Alerts - baoquankhu1.vn
Does Bezuclastinib’s Real-Time FDA Review and NDA Filing Change The Bull Case For Cogent Biosciences (COGT)? - Yahoo Finance
Cogent Biosciences Inc Stock (COGT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.14%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):